Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 6392Neoplasms 5365Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2709Colorectal Neoplasms 2679Lung Neoplasms 2267Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1552Leukemia, Myeloid, Acute 1540Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1423Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1129Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1050Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 976Uterine Cervical Neoplasms 926Glioblastoma 920Carcinoma, Renal Cell 882Lymphoma, Large B-Cell, Diffuse 853Hodgkin Disease 777

Interventions

Piperacillin, Tazobactam Drug Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gram-Positive Bacterial Infections × Clear all
NCT00167999 2007-03-15

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
200 enrolled

Bacterial Infections, Escherichia coli Infections, Klebsiella Infections, Gram-Positive Bacterial Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡